(Reuters) - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults. The Food and Drug Administration decision marked the fourth approval for Eylea, an injectable medicine sold in partnership with French drugmaker Sanofi. "Today's approval gives patients with diabetic retinopathy and diabetic macular edema another therapy to treat this vision-impairing complication," Edward Cox, director of the FDA's Office of Antimicrobial Products, said in a statement. Regeneron shares were down 2.4 percent at $461.90 on the Nasdaq by 11:10 a.m. EDT (1510 GMT) on an off day for biotech stock indexes.
via Health News Headlines - Yahoo News http://ift.tt/1CYh4wA
No comments:
Post a Comment